Introduction {#Sec1}
============

The number of people living with AIDS from the 2017 global epidemic of AIDS is about 36.9 million with 940,000 of AIDS related death. In Cameroon, the prevalence of HIV is about 3.7% in 2018 and about 510,000 people is living with HIV AIDS. Timely and appropriate initiation of antiretroviral treatment for HIV-positive subjects reduces morbidity and mortality associated with infections \[[@CR1]--[@CR5]\]. Moreover, eligibility for antiretroviral therapy for HIV/AIDS and monitoring progression of the disease commonly have been based on the number of CD4+ T lymphocytes in a patient's venous blood \[[@CR6]--[@CR8]\]. In the context of the HIV and AIDS pandemic, the enumeration of CD4 antigen-positive T cells is used to determine the immune status of patients with immune deficiencies such as HIV/AIDS or suspected of becoming so. Cameroon has an HIV prevalence rate estimated at 3.7% with a strongly represented rural area \[[@CR9], [@CR10]\]. In this context, new tools for diagnosis and treatment are needed to improve care. In the context of good laboratory practice, the introduction of a new diagnostic tool requires an evaluation of the performance characteristics. In 2012, there was an emerging technology in point of care for the determination of CD4+ T lymphocytes with the aim to reduce problems of collection and transportation of samples and to reduce time delay for the results to patients. Previously, after analysis with conventional flow cytometry testing, the CD4 results may be available between two or more days after blood sampling, delaying the start of treatment for newly diagnosed patients and increasing the risk of loss-to-follow-up \[[@CR11]\]. The introduction of point-of-care CD4+ cell counters in low income countries can improve access to quick and reliable CD4+ T-cell counts in HIV-positive patients because access to care and enabling initiation of treatment during a visit increase the efficiency and effectiveness for monitoring and staging of HIV patients \[[@CR12], [@CR13]\]. Absolute CD4+ cell count (AbsCD4) is a robust surrogate marker for immune competence in HIV-infected adults. However, percentage of CD4+ cells in the lymphocyte population (% CD4) has been considered a reliable surrogate marker for children less than 5 years of age, since the AbsCD4 count varies more than %CD4 due to the lymphocyte development cycle \[[@CR14], [@CR15]\]. In this study, the BD FACSPresto CD4 T cell counts were compared with BD FACSCalibur, BD facscount and Alere PIMA. In the national quality control program for external evaluation of CD4 coordinated by CIRCB reference laboratory, in collaboration with QASI of the Public Health Agency of Canada, each instruments passed in the year 2017 a quality control without any failure results. This is the first study done to compare the performance of instruments in our field context and this evaluation of the BD FACSPresto system comprised accuracy, precision and linearity. The CIRCB was commissioned to evaluate the BD FACSPresto ™ which is an automated system, CE IVD, designed for in vitro diagnostic use to perform direct enumeration of the absolute rate and percentage of CD4+ lymphocytes and the concentration of hemoglobin (Hb) in human blood. This is a prospective study to determine the relative bias between the BD FACSPresto ™ system and other CD4 counting devices present in Cameroon that perform an average of 5000 CD4+ T cell count tests per year. These are the BD FACSCalibur ™, reference device, BD FACSCount ™ and Alere PIMA. The choice of sites was based on the availability of the counting device and reagents.

Materials and methods {#Sec2}
=====================

Blood samples were obtained from patients undergoing routine CD4 monitoring at CIRCB, BIKOP, CASS de Nkolndongo and CMC of Nkolodom in Yaounde. All analyses were conducted in the medical analysis of each Unit. All specimens were processed within 24 h of collection. Blood was collected in K3-EDTA tubes and inverted several times to ensure proper mixing. For analysis on the FACSPresto analysis, a drop of blood from a Pasteur pipette was loaded onto the FACSPresto cartridge and capped and incubated at room temperature for 18 min; following incubation the cartridge was loaded onto the analyzer. For analysis on the PIMA, a drop of blood was loaded onto the cartridge and inserted into the analyzer. The TruCount method on the FACSCalibur was performed as the reference standard. In brief, 20 μl of BD Multitest fluorescent conjugated monoclonal antibodies, and 50 μl of whole blood were added to the TruCOUNT tube and vortexed for 5 s. The Multitest consists of CD3-FITC/CD8-PE/CD45-PerCP/CD4 APC reagent. The mixture was incubated for 15 min at room temperature in the dark before adding 450 μl of FACS™ lysing solution and incubating for an additional 15 min in the dark prior to acquisition on the FACSCalibur. Data were analyzed using the MultiSET™ software with automated gating and analysis. Analysis were conducted concurrently on the FACSCalibur, the FACSPresto, the FACSCount and the PIMA in a subset of specimens. Analyses were conducted on all 4 platforms for 265 specimens. Each operator had received adequate training on the use of reverse pipetting technique. All operators received training on the performance of the assay by the manufacturer. A total of 4 operators were involved in the evaluation. Maintenance and instrument calibration was performed according to the manufacturer's guidelines and done prior to initiation of the evaluation. Internal quality control was monitored routinely and the labs participated in an external quality assurance program with the Cameroon National Quality Assurance Program for CD4 enumeration in collaboration with QASI in Canada and the lab that conducted the BD FACSCalibur subscribes also to the United Kingdom National External Quality Assurance Service (UK-NEQAS) for CD4 testing.

Statistical methods {#Sec3}
-------------------

CD4+ T cell counts obtained from the FACSPresto device were compared to the FACSCalibur, FACSCount and PIMA. The amount of hemoglobin obtained from FACSPresto device were compared to the hematology device present in each center. Descriptive statistics was used to describe the data. Differences in parameters between the two groups were determined by Wilcoxon signed rank test and paired t-test. Passing--Bablok regression was used for the method correlation and correlation coefficients were determined. To determine the bias between the platforms, Bland--Altman analysis was done. The bias was defined as the mean difference between two methods. The limits of agreement were calculated as the mean ± 1.96 Standard Deviation (SD) of the differences of the results obtained. Confidence intervals for the bias and the limits of agreement were calculated. Pollock analysis was done to calculate the relative bias and the limits of agreement, which were defined as the mean ± 1.96 SD of the relative mean bias of paired measurements. The data was plotted with the y-axis representing the % difference relative to the absolute value (x-axis) of the comparator test. We determined the percentage similarity between a sample pair and defined it as the average between the methods divided by the comparator method multiplied by 100. The same analysis was done for comparing CD4% values on the FACSPresto, the FACSCount and the FACSCalibur. The coefficient of repeatability was calculated and was defined as the variation in triplicate measurements for 29 specimens, performed on the same instrument by a single technician under the same conditions. Coefficient of repeatability below 5% were considered optimal, coefficients between 5 and 10% were considered acceptable. Data was stratified into two groups based on CD4 count above or below 350 cells/μl and 500 cells/μl and CD4% above or below 25%. Agreement between the results obtained on the different platforms at CD4 counts below thresholds of 350 cells/μl and 500 cells/μl was determined using kappa statistics. We applied the Landis-Koch interpretation scale (kappa values of \< 0.40 indicate poor agreement; \> 0.40 and \< 0.75 fair to good agreement and \> 0.75 excellent agreement).

Ethical review {#Sec4}
--------------

The Cameroon National Ethics Committee approved the protocol prior to implementation with the number 2016/08/754/L/CNERH/SP. Blood samples were collected in the context of routine CD4 count testing for patients at CIRCB and other health facilities. Written informed consent is not required for receipt of routine services including CD4 testing performed at MOH facilities. Residual blood from routine testing was used for the analysis. No personally identifiable information was made available to the researchers. The institutional review boards waived the need for written informed consent.

Results {#Sec5}
=======

Specimens collected from patients were tested on the FACSCalibur, FACSPresto, FACSCount and PIMA. The FACSPresto and FACSCalibur are present at CIRCB. PIMA Alere and BD FACSCount are present at BIKOP and CMC of Nkolondom respectively. CD4 devices used in this work are representative in Cameroon according to the number of tests per year. Each CD4 device is doing per year more than 5000 CD4 enumeration tests (personal data).

69 samples were tested on PIMA and FACSPresto (Fig. [1](#Fig1){ref-type="fig"}) with the ration of 0.28 between men and woman, 96 samples were tested on FACSCount and FACSPresto (Fig. [2](#Fig2){ref-type="fig"}) with the ratio of 0.32 between men and woman and 245 samples were tested on FACSCalibur and FACSPresto (Fig. [3](#Fig3){ref-type="fig"}) with the ratio of 0.26 between men and woman.Fig. 1Comparison between FACSPresto and PIMA. Passing-Bablok regression plot comparison of **a** absolute CD4 count values obtained from FACSPresto with the PIMA as reference standard. The solid line represents the regression line and dashed line the 95% CI. Pollock plots indicating  %mean bias between **b** absolute CD4 counts values obtained on FACSPresto compared with those obtained on the FACSCount. The solid line represents the mean bias, the dashed line represents mean bias ± 1.96SDFig. 2Comparison between FACSPresto and FACSCount. Passing-Bablok regression plot comparison of **a** absolute CD4 count and **c** CD4% values obtained from FACSPresto with the FACSCount as reference standard. The solid line represents the regression line and dashed line the 95% CI. Pollockplots indicating %mean bias between **b** absolute CD4 count and **d** CD4% values obtained on FACSPresto compared with those obtained on theFACSCount. The solid line represents the mean bias, the dashed line represents mean bias ± 1.96SDFig. 3Comparison between FACSPresto and FACSCalibur. Passing-Bablok regression plot comparison of **s** absolute CD4 count and **c** CD4% values obtained from FACSPresto with the FACSCalibur as reference standard. The solid line represents the regression line and dashed line the 95% CI. Pollock plots indicating %mean bias between **b** absolute CD4 count and **d** CD4% values obtained on FACSPresto compared with those obtained on the FACSCalibur. The solid line represents the mean bias, the dashed line represents mean bias ± 1.96SD

A total of 245 patients were enrolled in this technical accuracy evaluation. During the study, we processed the EQA sample from QASI and the values obtained by different devices were proficient.

The BD FACSPresto evaluated had CE-IVD and WHO-PQ (pre-qualification) approval. Approximately 75% of enrolled patients were female while 33% and 53% of patients had a CD4+ T cell count above 350 cells/ul, and 500 cells/µl as measured by the BD FACSCalibur. The mean and median ages of enrolled participants were 36 Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of study participantsMenFemaleChildrenTotalParticipants4615841245Mean age39.4140.86935.46T CD4 absolute value Mean FACSCalibur4354941236588 Mean FACSPresto4364801286589 Mean FACSCount433494925484 Mean PIMA4235021248507% T CD4 Mean %FACSCalibur23.2425.8432.9326 Mean %FACSPresto22.3224.530.7325 Mean %FACSCount21.3225.0723.7523

Samples tested using the BD FACSCalibur had a median of 609 cells/ul (range: 5--1776 cells/ul), compared with a median of 608 cells/ul (range: 6--1607 cells/ul) on the BD FACSCount compared with a median of 563 cells/ul (range: 6--1635 cells/ul) on the BD FACSPresto and a median of 540 cells/µl on the Alere PIMA. The patient distributions by technology and CD4+ T cell threshold can be found in Table [1](#Tab1){ref-type="table"}.

The BD FACSCalibur and BD FACSPresto classified 33% and 30% of enrolled patients as above 350 cells/ul, respectively. The Alere PIMA and BD FACSPresto classified 30% and 25% of enrolled patients as above 350 cells/µl respectively.

The BD FACSCount and BD FACSPresto classified 39% and 37% of enrolled patients as above 350 cells/µl respectively.

Discussion {#Sec6}
==========

The Spearman correlation coefficient is good for all three instruments compared to BD FACSPresto and the P value is less than 0.05 (Table [2](#Tab2){ref-type="table"}). An important bottleneck for the extension of patient care services and ARV treatment in Cameroon is the access to diagnosis for the identification and classification of patients faced with difficulties such as stock-outs, equipment maintenance. The introduction of rapid testing for HIV in the last decade has facilitated people's access to HIV testing services, followed by care and treatment services. Access to local CD4 tests has been made possible thanks to the PIMA devices of the ALERE group \[[@CR16], [@CR17]\] but remains insufficient and limited because a good portion of the population aged 0 to 5 years does not have access to this test directly because it requires using a hematology device to get the percentage.Table 2Coefficient of Spearman and p-value between BD FACSPresto and other instrumentsSpearman\'s rank correlation coefficientP-valueVariablesBD FACSPresto™ CD4BD FACSPresto™ CD4BD FACSCalibur™ CD4*0.9810.0001*BD FACSPresto™ CD4*1*0BD FACSCount™ CD4*0.974*\< *0.0001*PIMA CD4*0.963*\< *0.0001*The values in italic are different from 0 to a significant level alpha = 0.05

The follow-up of children under 5 years benefits from measuring the percentage of CD4+ T cells with BD FACSPresto ™ while the PIMA does not give this value which is important in improving the management of these patients. The BD FACSPresto ™ has the advantage of providing in absolute value and percentage CD4+ T cells as well as the hemoglobin level in addition to the fact that it can make between 60 and 80 samples per day.

The internal quality control does not require additional reagents or cartridges, and it reads the external quality control samples provided by QASI and UKNEQAS without any problem. It is easy to use because everything is shown in video image on the touch screen of the device. It can be used in rural areas where electrical problems are lacking because it has a battery that has a battery life of 6 h. It does not require accessory instruments, computers, pipettes or consumables (other than lancets, swabs and gloves) for sampling. Cartridges can be stored at room temperature, as the cold chain is no longer available. Necessary thereby reducing the cost of transport and storage. The results are stored by the instrument up to 12,000. The BD FACSPresto ™ device has features that are suitable for use in districts and rural health centers improving access to care and reducing mortality and morbidity \[[@CR18]\]. It will also reduce queues while reducing patient visits to health facilities as patients with immunodeficiency are prioritized and expected to reduce energy costs. Similar studies have been done in Kenya and many other countries using whole blood with EDTA anticoagulant and capillary blood to see the correlation \[[@CR19]--[@CR23]\]. The slight discrepancy between the individual results of BD FACSPresto ™ and other devices in this study was similar to those seen and accepted in other comparisons of conventional CD4 technologies (Additional file [1](#MOESM1){ref-type="media"}). The discrepancy is likely to be due to an error caused by variations in blood collection or pipetting.

Conclusion {#Sec7}
==========

Given the low sensitivity and high upward misclassification rates, it would be worthwhile to understand the performance of the BD FACSPresto in sicker populations of HIV-positive patients. Given the need to expand access to CD4+ T cell testing for pre-ART patient management and replace old or broken conventional technologies, the BD FACSPresto performs well in the laboratory setting and could be considered in rational deployment of future POC CD4+ T cell technologies.

Study limits {#Sec8}
------------

The study was conducted at CIRCB where the staff is qualified and the blood collected in EDTA tubes. Tests on capillary blood have not been done and it would be necessary to perform them in rural areas where the conditions are very different in terms of personnel and workload. Information on the cost of the test and the cost of the device was not provided.
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**Additional file 1.** Summary of various CD4+ T cells enumeration techniques.
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